About Biopharmaceuticals Engineering at UD
Biopharmaceuticals—medicines produced from living cells—have the potential to revolutionize the treatment of cancers, Alzheimer’s Disease, and inflammatory disorders such as rheumatoid arthritis.
The University of Delaware is home to the National Institute for Innovation in Biopharmaceuticals, a national partnership of 120 universities, community colleges, corporations, government agencies and nonprofit organizations aimed at advancing biopharmaceutical manufacturing innovation and workforce development. The institute director is Kelvin Lee, Gore Professor of Chemical & Biomolecular Engineering at the University of Delaware. NIIMBL is one of 14 Manufacturing USA institutes focused on fundamentally advancing U.S. competitiveness in key industries.
Many researchers across the University of Delaware, including faculty members and students in the College of Engineering, are working on key questions around biopharmaceutical innovation, such as how to extend the shelf life of these medicines and much more.
226,636 sq ft
The Ammon-Pinizzotto Biopharmaceutical Innovation Center now under construction on UD’s STAR Campus will house NIIMBL, the Delaware Biotechnology Institute, and UD’s biomedical engineering program, as well as research laboratories in pharmaceutical discovery and molecular and medical sciences.
Global leaders and experts in biotechnology and life sciences toured the University of Delaware’s STAR Campus
‘Fireside Chat’ explores priorities, potential and perils of health-related research.
Kelvin Lee has received the 2019 Marvin J. Johnson Award in Microbial & Biochemical Technology from the American Chemical Society’s Division of Biochemical Technology.
University of Delaware Professors Kelvin Lee and Abraham Lenhoff offer insight on shelf life differences in a special class of biopharmaceutical drugs called monoclonal antibodies.